Bayer AG has hit the acquisition trial again to buy privately owned US group Asklepios BioPharmaceutical, Inc. (AskBio), strengthening the German major's presence in the cell and gene therapy space.
Bayer Boosts Gene Therapy Presence With AskBio Buy
Deal Could Be Worth $4bn
After buying BlueRock Therapeutics outright last year, the Leverkusen-headquartered group has put down $2bn up front to acquire another cell and gene therapy specialist in Asklepios BioPharmaceutical.
